Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

The New England journal of medicine, Volume: 367, Issue: 16
October 18, 2012
Myungsun Lee M, Jongseok Lee J, Matthew W Carroll MW, Hongjo Choi H, Seonyeong Min S, Taeksun Song T, Laura E Via LE, Lisa C Goldfeder LC, Eunhwa Kang E, Boyoung Jin B, Hyeeun Park H, Hyunkyung Kwak H, Hyunchul Kim H, Han-Seung Jeon HS, Ina Jeong I, Joon Sung Joh JS, Ray Y Chen RY, Kenneth N Olivier KN, Pamela A Shaw PA, Dean Follmann D, Sun Dae Song SD, Jong-Koo Lee JK, Dukhyoung Lee D, Cheon Tae Kim CT, Veronique Dartois V, Seung-Kyu Park SK, Sang-Nae Cho SN, Clifton E Barry CE

Linezolid has antimycobacterial activity in vitro and is increasingly used for patients with highly drug-resistant tuberculosis.

Courtesy of the U.S. National Library of Medicine